The role of brigatinib in crizotinib-resistant non-small cell lung cancer by Mezquita L, Planchard D

Subjects: Get full text

Hypersensitivity in ALK-positive lung cancers exposed to ALK inhibitors: a case of successful switch to an alternative ALK inhibitor and systematic review of the literature by Deng L, Sharma J, Ravera E, Halmos B, Cheng H

Subjects: Get full text

Safety of brigatinib following alectinib-induced-pneumonitis: Case report by Blerina Resuli, Heidi Galarza, Laura Elsner, Diego Kauffmann-Guerrero, Jürgen Behr, Amanda Tufman

Subjects: Get full text

Sharing Experience with Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors in Lung Cancer: An Italian Expert Panel Discussion by Cesare Gridelli, Marcello Tiseo, Diego Luigi Cortinovis, Maria Rita Migliorino, Vito Barbieri, Paolo Bironzo, Alessandra Bearz, Ilaria Attili, Filippo de Marinis

Subjects: Get full text

Alectinib versus crizotinib in ALK‐positive advanced non‐small cell lung cancer and comparison of next‐generation TKIs after crizotinib failure: Real‐world evidence by Yurong Wang, Shujing Shen, Peizhu Hu, Di Geng, Ruipan Zheng, Xingya Li

Subjects: Get full text

The likelihood of being helped or harmed as a patient-centred tool to assess ALK-Inhibitors clinical impact and safety in ALK-addicted non-small cell lung cancer: A systematic revi... by Luca Mastrantoni, Giulia Giordano, Emanuele Vita, Guido Horn, Jacopo Russo, Armando Orlandi, Gennaro Daniele, Diana Giannarelli, Giampaolo Tortora, Emilio Bria

Subjects: Get full text

Formulation of Chitosan-Coated Brigatinib Nanospanlastics: Optimization, Characterization, Stability Assessment and In-Vitro Cytotoxicity Activity against H-1975 Cell Lines by Randa Mohammed Zaki, Munerah M. Alfadhel, Saad M. Alshahrani, Ahmed Alsaqr, Layla A. Al-Kharashi, Md Khalid Anwer

Subjects: “…brigatinib…”
Get full text

Brigatinib treated ALK positive lung squamous cell carcinoma after failed chemotherapy: A case report by Shuluan Li, Pei Zhang, Tianyu Wang, Jie Wang, Jianchun Duan

Subjects: Get full text

Sustained Improvement in the Management of Patients with Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocation: Where Are We Running? by Gianluca Spitaleri, Pamela Trillo Aliaga, Ilaria Attili, Ester Del Signore, Carla Corvaja, Chiara Corti, Edoardo Crimini, Antonio Passaro, Filippo de Marinis

Subjects: Get full text

Case report: The effect of induction targeted therapies in stage III driver mutants non-small cell lung cancer by Waleed Kian, Waleed Kian, Waleed Kian, Belal Krayim, Betsy Giles, Nasim A. Elkiaan, Amjad Idris, Daniel Fink, Nir Peled, Laila C. Roisman

Subjects: “…brigatinib…”
Get full text

Brigatinib can inhibit proliferation and induce apoptosis of human immortalized keratinocyte cells by Qi Yang, Dan Zhao, Linjie Ju, Peng Cao, Jifu Wei, Zhixian Liu

Subjects: “…brigatinib…”
Get full text

Current Insights on the Treatment of Anaplastic Lymphoma Kinase-Positive Metastatic Non-Small Cell Lung Cancer: Focus on Brigatinib by Rijavec E, Biello F, Indini A, Grossi F, Genova C

Subjects: “…brigatinib…”
Get full text

Randomized, open-label phase II study of brigatinib and carboplatin plus pemetrexed and brigatinib alone for chemotherapy-naive patients with ALK-rearranged non-squamous non-small... by Kazushige Wakuda, Hirotsugu Kenmotsu, Yuki Sato, Atsushi Nakamura, Hiroaki Akamatsu, Motoko Tachihara, Satoru Miura, Toshihide Yokoyama, Keita Mori, Kazuhiko Nakagawa, Nobuyuki Yamamoto

Subjects: Get full text

Cost-utility analysis of brigatinib compared to alectinib in the treatment of ALK-positive NSCLC in patients previously not treated with an ALK inhibitor by Roberto Ravasio, Holly Cranmer, Izzie Kearns, Raffaella Viti, Simone Corinti

Subjects: Get full text

Treatment of anaplastic lymphoma kinase-positive lung adenocarcinoma with pemetrexed and carboplatin after crizotinib failure and significant liver dysfunction; a case report by Oranus Mohammadi, Kayla Haines, Mohammad Jahanzeb

Subjects: Get full text

Early Onset Pulmonary Events and Management Strategies during the Treatment of 
ALK Positive NSCLC Patients with Brigatinib by Mingyi YANG, Weichi LUO, Qing ZHOU

Subjects: Get full text

Brigatinib treatment in a patient with advanced NSCLC with XPO1-ALK fusion: a case report by Yang Zhang, Ke-jie Li, Can Wang, Chang-lin Zou, Meng Su

Subjects: Get full text

A novel double fusion of EML4-ALK and PLEKHA7-ALK contribute to rapid progression of lung adenocarcinoma: a case report and literature review by Zhongzhao Wang, Yang Luo, Heng Gong, Yang Chen, Hao Tang

Subjects: Get full text

Brigatinib-repurposed chemo-photodynamic therapy nanoplatform via effective apoptosis against colorectal cancer by Miao Su, Hailong Tian, Li Zhou, Qiong Li, Shuqi Wang, Canhua Haung, Edouard C. Nice, Shaojiang Zheng, Jingquan Li

Subjects: Get full text

Rapid response to fifth-line brigatinib plus entrectinib in an ALK-rearranged lung adenocarcinoma with an acquired ETV6-NTRK3 fusion: a case report by Dan Li, Yue Zhu, Jincheng Song, Dafu Yang, Saiqiong Cui, Xin Liu, Le Wang, Jiangyan Zhang, Evenki Pan, Zhaoxia Dai

Subjects: Get full text